Radiolabelled peptides are used for specific targeting of receptors (over-)expressed by tumour cells. Dependent on the kind of labelling and the radionuclide used, these compounds may be utilised for imaging or for therapy. A concise overview is provided on basic principles of designing and developing radiopeptides for these applications. Furthermore, clinical application of these compounds for imaging and therapy is described. Advantages of the method compared to other techniques (such as the use of radiolabelled antibodies or antibody fragments) are discussed as well as pitfalls and limitations.

Author

Martin Gotthardt, Ingrid Dijkgraaf, Otto C Boerman and Wim J G Oyen

Contact Details

Corresponding address:
Martin Gotthardt,
Department of Nuclear Medicine,
Radboud University Nijmegen Medical Centre,
PO Box 9101, 6500 HB Nijmegen,
The Netherlands

Reference

ICIS Cancer Imaging Volume 6 Special Issue A
DOI: 10.1102/1470-7330.2006.9038

Date Posted

31 October 2006

Print PDF

Size

523.64 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	2 seconds
ADSL 512Kb/s (Broadband):	8 seconds
64 Kb/s (ISDN):	1 minute 5 seconds
33.3 Kb/s (Typical Modem):	2 minutes 5 seconds

Screen PDF

Size

396.58 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	6 seconds
64 Kb/s (ISDN):	49 seconds
33.3 Kb/s (Typical Modem):	1 minute 35 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 66356, London, E14 1GW. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.